These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32116806)

  • 1. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.
    Mallaroni P; Mason NL; Vinckenbosch FRJ; Ramaekers JG
    Psychopharmacology (Berl); 2022 Jun; 239(6):1783-1796. PubMed ID: 35487983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
    Barnett BS; Ziegler K; Doblin R; Carlo AD
    J Psychopharmacol; 2022 Oct; 36(10):1118-1128. PubMed ID: 35971893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
    Jones G; Lipson J; Nock MK
    Sci Rep; 2022 Jun; 12(1):10578. PubMed ID: 35732796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.
    Zeifman RJ; Singhal N; Breslow L; Weissman CR
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):436-451. PubMed ID: 33860173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classic psychedelics, health behavior, and physical health.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    Ther Adv Psychopharmacol; 2022; 12():20451253221135363. PubMed ID: 36465958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulant and hallucinogenic novel psychoactive substances; an update.
    Schifano F; Vento A; Scherbaum N; Guirguis A
    Expert Rev Clin Pharmacol; 2023; 16(11):1109-1123. PubMed ID: 37968919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelics not linked to mental health problems or suicidal behavior: a population study.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2015 Mar; 29(3):270-9. PubMed ID: 25744618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.